TrenibotE / BoNT-E
Investigational rapid-onset, short-duration BoNT-E
이 치료에 대해
TrenibotE is an investigational botulinum toxin serotype E from AbbVie/Allergan Aesthetics. It is designed for rapid onset around 8 hours and short duration around 2-3 weeks, but as of April 2026 the US FDA issued a Complete Response Letter related to manufacturing. It is not approved.
작용 기전
BoNT-E also cleaves SNAP-25 but is expected to have faster onset and shorter duration than BoNT-A. Clinical use should wait for approval.
적응증
기대 효과
Phase 3 data have been reported for rapid onset and short duration, but as of June 21, 2026 it remains unapproved, so it should be listed as watchlist / not offered.
임상 근거
위험 및 부작용
Not available for routine clinical use before approval. Expected toxin-class risks include bruising, headache, eyelid ptosis, asymmetry and rare swallowing or breathing symptoms.